G

Genentech

Biotech firm creating medicines via R&D

Vice President - Medical Affairs, Neurology

Full-Time
$356.2k - $467.5k/yr+ Annual bonus
Expert
PhD, MD
South San Francisco, CA, USA
In PersonRelocation assistance is available.

About the job

Requirements
  • An advanced scientific or clinical degree is required, specifically an MD, PhD, or equivalent; MD is preferred.
  • A minimum of 15 years of biopharmaceutical industry experience with significant medical affairs leadership responsibility is required.
  • Deep expertise in neurology or neuroscience and recognition within the neurology practitioner environment are required.
  • Proven success leading complex, matrixed medical affairs organizations is required.
  • Demonstrated experience in launch excellence, lifecycle strategy, and evidence generation is required.
  • Strong understanding of the evolving healthcare ecosystem, including payer, policy, and patient dynamics, is required.
  • Exceptional leadership, communication, collaboration, and stakeholder engagement skills are required.
  • Demonstrated ability to influence across highly matrixed United States and global organizations is required.
Responsibilities
  • Develop and execute an integrated medical strategy for the neurology portfolio aligned with enterprise and patient priorities.
  • Shape the future direction of neurology medical affairs through innovation, scientific leadership, and operational excellence.
  • Drive launch readiness years ahead of anticipated launches and lifecycle medical strategy across the portfolio.
  • Translate scientific insights, patient needs, care gaps, and clinical insights into measurable medical strategies that improve patient outcomes and healthcare delivery.
  • Anticipate and address emerging trends in neuroscience, evidence generation, digital health, and stakeholder engagement.
  • Ensure medical strategies are aligned with broader United States and global medical priorities and organizational objectives.
  • Serve as an enterprise leader within United States Medical, contributing beyond neurology to advance organizational priorities, culture, and capabilities across Genentech United States Medical.
  • Build collaborative partnerships across therapeutic area leaders to drive alignment, share best practices, and foster a unified One Medical mindset.
  • Partner with global medical leadership to ensure strategic alignment and coordination across United States and global priorities.
  • Collaborate across Medical, Clinical Development, Marketing, Commercial, Market Access, Health Economics and Outcomes Research, Regulatory, Safety, Patient Advocacy, Public Affairs, and Field Medical organizations.
  • Operate with an enterprise perspective and organizational agility while balancing therapeutic area priorities with broader business and patient needs.
  • Build alignment with the Head of United States Medical Affairs and translate organizational vision into execution, culture, and measurable impact.
  • Foster collaboration, transparency, accountability, and shared success across headquarters teams and field medical teams.
  • Maintain and establish critical relationships and partnerships with healthcare professionals, community and academic institutions, patient advocacy groups, and key external stakeholders across neurology.
  • Lead external engagement strategy and represent the organization at scientific congresses, advisory boards, and other key forums.
  • Drive high-quality scientific exchange with field teams and evidence dissemination with integrity and patient focus.
  • Translate external insights into actionable medical strategy and organizational learning across the enterprise.
  • Oversee integrated, multimodal evidence generation strategies, including customized approaches to real-world evidence, investigator-sponsored research, health outcomes research, publication planning, and other appropriate approaches.
  • Champion innovative approaches to medical insights, digital engagement, analytics, and evidence generation.
  • Advance modern medical affairs capabilities, including artificial intelligence-enabled insights, omnichannel engagement, and data-driven decision-making.
  • Ensure medical strategies incorporate patient perspectives and evolving healthcare system needs.
  • Drive continuous improvement and modernization of medical affairs capabilities and operating models.
  • Lead and demonstrate what a high-performing, inclusive, and collaborative neuroscience medical organization operates like within the One Medical context.
  • Build a culture grounded in accountability, agility, collaboration, inspiration with action, innovation, transparency, and continuous learning.
  • Develop future leaders and strengthen organizational capability through coaching, mentorship, and talent planning.
  • Create clarity, alignment, and energy during periods of change and organizational evolution.
  • Inspire teams and colleagues with a positive, solutions-oriented, and forward-looking leadership approach.
  • Foster a safe environment where teams are empowered to innovate, collaborate, and challenge legacy thinking constructively.
Desired Qualifications
  • Experience leading organizational transformation or capability modernization initiatives.
  • Experience integrating digital innovation, analytics, and artificial intelligence-enabled approaches into medical affairs.
  • Global or international leadership experience.
  • A track record of building high-performing teams and inclusive cultures.
  • Experience collaborating across multiple therapeutic areas within enterprise leadership structures.
  • Demonstrated success driving cross-functional alignment and enterprise change initiatives.

About the company

Genentech is a biotechnology company focused on researching and developing medicines and therapies to address unmet medical needs. It uses large-scale R&D, with about 13,500 employees and 40 approved medicines; it develops biologics and other therapies marketed through healthcare providers, generating revenue from sales. It differentiates itself with a large patent portfolio (around 20,000 patents) and multiple FDA Breakthrough Therapy Designations, along with a patient-centric approach that weighs access and affordability. Its goal is to advance medical science and deliver high-quality, effective therapies that improve patient health and support the broader medical community.

Company Size

10,001+

Company Stage

Grant

Total Funding

$47.8M

Headquarters

San Francisco, California

Founded

1976

Get referred to Genentech

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 Boston Innovation Center expands CVRM hiring and AI-driven drug discovery.
  • September 24, 2026 Earendil Labs deal adds oncology bispecifics with $1.5 billion potential value.
  • September 2026 DualityBio ADC partnership targets resistance beyond topoisomerase-based therapies.

What critics are saying

  • September 2026 closed a 40-year cancer drug plant, cutting 265 jobs in South San Francisco.
  • Roche now relies on external partners for bispecifics and ADCs, weakening internal discovery edge.
  • If Roche's U.S. R&D and manufacturing buildout misses returns, Genentech loses strategic capital priority.

What makes Genentech unique

  • Roche backs Genentech with global commercialization reach and deep oncology development infrastructure.
  • September 2026 Boston CVRM center adds end-to-end discovery through late-stage development capability.
  • Genentech still wins platform partnerships like Earendil Labs and DualityBio in 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

↓ -3%

1 year growth

↓ -3%

2 year growth

↓ -3%
Pharmaceutical Executive
Sep 25th, 2026
Roundup: Nanexa, Earendil Labs, and Atavistik Bio enter platform deals with Novo Nordisk, Genentech, and Roche.

Roundup: Nanexa, Earendil Labs, and Atavistik Bio enter platform deals with Novo Nordisk, Genentech, and Roche. Three platform-technology deals paired Nanexa, Earendil Labs, and Atavistik Bio with Novo Nordisk, Genentech, and Roche to advance next-generation metabolic and oncology medicines. Platform-technology deals dominated this week's dealmaking, as drug delivery and discovery specialists licensed their proprietary systems to larger partners chasing next-generation metabolic and oncology medicines. Nanexa licenses Pharmashell platform to Novo Nordisk. Nanexa AB entered into a global exclusive license and collaboration agreement with Novo Nordisk for the use of the Pharmashell technology platform for certain peptide-based drugs targeting obesity, type 2 diabetes, and other cardiometabolic indications. As part fo the deal, Nanexa is eligible to receive total payments upwards of $1.33 billion, including $701 million in upfront payment and development and regulatory milestones, with the remaining milestone payments tied to sales.[1] Nanexa is also eligible to receive low single-digit royalties on global net sales of products developed under the agreement.[1] Under terms of the agreement, Novo is expected to receive a global license to use Nanexa's Pharmashell technology platform in up to five development programs.[1] The collaboration includes development of long-acting injectable formulations with different administration-frequency profiles, with monthly and quarterly administration as target profiles. Pharmashell is Nanexa's proprietary atomic layer deposition-based drug delivery platform, designed to enable controlled and sustained release of active pharmaceutical ingredients through an ultra-thin inorganic coating applied to individual drug particles, intended to support differentiated long-acting injectable drugs that reduce dosing frequency and improve the treatment experience for people living with chronic metabolic or cardiovascular disease.[1] "We are very excited about and proud of this license agreement with Novo and look forward to working with them to successfully develop products with less frequent dosing in obesity and type 2 diabetes indications. Following our license and option agreement with Moderna in 2025, this agreement further strengthens the external validation of Pharmashell as a broadly applicable drug delivery platform and we believe this provides a strong foundation for expanding Pharmashell into additional therapeutic areas and to selectively advance additional internal programs towards clinical proof of concept, allowing us to capture greater value from the breadth of the Pharmashell platform," said David Westberg, CEO of Nanexa. Earendil Labs partners with Genentech. Earendil Labs announced a research collaboration with Genentech, a member of the Roche Group, to discover and develop multiple therapeutic bispecific antibody programs in oncology. Earendil Labs will receive a $55 million upfront payment, and the total potential value of the collaboration, including upfront, development, regulatory and sales milestone payments is expected to excess $1.5 billion.[2] Earendil Labs is also eligible to receive tiered royalties on net product sales. Under the collaboration, Earendil Labs will lead antibody discovery and research through the early clinical development stage for antibody programs directed to certain pre-agreed target combinations, while Genentech will assume responsibility for subsequent global clinical development and commercialization of antibody programs arising from the collaboration.[2] "Genentech is a pioneer in defining modern biologics cancer medicine. Earendil Labs is building an AI-driven high-throughput biology platform that effectively integrates AI directly into biologics research and development - from predictive protein modeling and generative protein design to rapid experimental validation. By combining our platform with Genentech's deep expertise in oncology drug development, we aim to accelerate the creation of differentiated bispecific antibodies and translate them into new medicines," said Jian Peng, PhD, CEO of Earendil Labs. Atavistik Bio strikes CVRM discovery collaboration with Roche. Atavistik Bio entered into a strategic research collaboration with Roche to discover and develop novel small molecule therapeutics against multiple targets for cardiovascular, renal, and metabolic diseases. As part of the deal, Atavistik Bio is set to receive an upfront payment of $70 million and may be eligible to receive additional research, development, and commercial milestone payments of up to $1.9 billion, along with tiered royalties on future net sales of any approved medicines resulting from the collaboration.[3] The collaboration will leverage Atavistik Bio's proprietary Amps drug discovery platform and expertise in allosteric drug discovery to identify novel functional binding pockets and advance selective small molecule therapeutics against targets for cardiovascular, renal, and metabolic disease.[3] By uncovering cryptic, biologically relevant binding pockets, Atavistik Bio's platform enables new approaches to develop differentiated small molecules against therapeutically important targets that have historically been challenging to modulate. Under the terms of the agreement, Atavistik Bio will be responsible for discovery and research activities for the collaboration targets, with Roche responsible for further preclinical and clinical development, regulatory, and commercialization activities.[3] "We are pleased to partner with Roche, whose deep expertise in drug development makes them an ideal partner to extend the reach of our allosteric discovery platform," said Bryan Stuart, chief executive officer of Atavistik Bio. "This collaboration reflects the strength and broad applicability of our platform across therapeutic areas, further validating our approach to allosteric drug discovery. We are excited to extend the application of our platform into CVRM diseases by leveraging Roche's deep expertise in the field, while we remain focused internally on advancing a robust pipeline of potentially best-in-class therapies for patients with rare hematologic diseases."

European Biotechnology
Sep 25th, 2026
Roche signs two deals worth about $3.5B in one day.

Roche signs two deals worth about $3.5B in one day. Roche signed two research partnerships on Sept. 24: one with Atavistik Bio to discover drugs for cardiovascular, renal and metabolic diseases, and another with Earendil Labs to develop cancer antibodies. Together, the agreements have a potential value of more than $3.47 billion (€3.05 billion). Roche is paying $125 million (€110 million) upfront. Atavistik: Roche will pay the Cambridge, Massachusetts, biotech $70 million (€62 million) upfront, with up to $1.9 billion (€1.67 billion) in research, development and commercial milestones, plus royalties. Atavistik will use its AMPS platform to find binding pockets on proteins and design small molecules against several disease targets. Roche will take over further preclinical development, clinical trials and commercialization. * The deal takes Atavistik's discovery platform beyond its own focus on rare blood diseases. Its lead drug, ATV-1601, is in a Phase 1/2 trial for hereditary hemorrhagic telangiectasia, a condition that causes abnormal blood vessels. Atavistik raised $160 million (€141 million) in its Series B financing and also has a research partnership with Pfizer. Earendil: Roche's Genentech unit will pay $55 million (€48 million) upfront to work with the Delaware-based biotech on multiple bispecific antibodies for cancer. The agreement is worth more than $1.5 billion (€1.32 billion) if its development, regulatory and sales milestones are met, with royalties on top. Earendil will lead discovery, research and early clinical development; Genentech will handle later global development and commercialization. The companies have not disclosed the target combinations. * Earendil says its platform combines AI-based protein design with rapid experimental testing. It has already partnered with Sanofi on bispecific antibodies for autoimmune and inflammatory diseases, and said in March that it had raised $787 million (€692 million) across financing rounds. The big picture: These are Roche's fourth and fifth announced biotech agreements in less than a month. Since Aug. 28, Genentech has partnered with DualityBio on antibody-drug conjugates, Roche has licensed Simcere Zaiming's trispecific antibody for B-cell diseases, and it has struck a separate bispecific discovery deal with Dualitas Therapeutics for inflammatory diseases. * The five deals carry more than $7 billion (€6.2 billion) in combined potential value, against $281.5 million (€248 million) in disclosed upfront payments. In four weeks, Roche has added three antibody partnerships, one antibody-drug conjugate collaboration and Atavistik's small-molecule platform to its external pipeline search. | (C) european biotechnology | Joachim Eeckhout 25 September 2026 |

DCBN
Sep 24th, 2026
Earendil Labs announces research collaboration with Genentech to discover and develop therapeutic bispecific antibodies in oncology.

Earendil Labs announces research collaboration with Genentech to discover and develop therapeutic bispecific antibodies in oncology. WILMINGTON, Del., Sept. 24, 2026 /PRNewswire/ - Earendil Labs, an AI-powered biotechnology company advancing next-generation biologics, today announced a research collaboration with Genentech, a member of the Roche Group, to discover and develop multiple therapeutic bispecific antibody...

Texas Border Business
Sep 22nd, 2026
Accelerator program relaunches oct. 15 with expanded focus on AI and healthcare.

Accelerator program relaunches oct. 15 with expanded focus on AI and healthcare. Sep 22, 2026 Listen to article (english) Translate text to Spanish or other 102 languages! Sep 1, 2026 Aug 28, 2026 Aug 25, 2026 Aug 3, 2026 - Advertisement - Texas Border Business - Advertisement - EDINBURG, Texas - AltaCair Foundation, in partnership with Genentech as the 2026 co-host, will host its fourth annual Accelerator summit on Thursday, October 15, 2026, from 8:00 a.m. to 12:00 p.m. at the Harlingen Convention Center. Accelerator 2026: Bridging Al & Health Outcomes will bring together healthcare, policy, nonprofit, technology and community leaders to explore how artificial intelligence can be used responsibly and practically to improve healthcare access, communication, and community health outcomes. The half-day summit will feature keynote speakers and panel discussions focused on whole-person care, social determinants of health, social impact and stronger community collaboration. - Advertisement - "Artificial intelligence is rapidly changing healthcare, but the conversation must remain centered on people," said Dr. Rashmi Chandran, CEO of AltaCair Foundation. "Accelerator 2026 will create space for leaders across sectors to explore how innovation can help remove barriers, strengthen access and improve health outcomes for communities throughout the Rio Grande Valley." Accelerator was created to bring regional leaders together around the issues shaping health and well-being in the Rio Grande Valley. Now entering its fourth year, the summit continues to turn conversation into collaboration and community-centered action. About AltaCair Foundation AltaCair Foundation is a Rio Grande Valley nonprofit organization working to create a healthier region by fostering collaborative partnerships that address the basic healthcare needs of underserved communities. Through community resource fairs, educational initiatives, regional convenings and access-focused programs, AltaCair connects organizations, resources and residents to create meaningful community impact. - Advertisement - Additional information regarding registration, speakers and sponsorship opportunities found at www.altacairaccelerator.com. - Advertisement - Sep 22, 2026 News Sep 22, 2026 - Advertisement -

Founder News
Sep 21st, 2026
Genentech axes 265 jobs as storied 40-year cancer drug plant closes

Genentech axes 265 jobs as storied 40-year cancer drug plant closes